Showing results (151-160 of 236) with videos related to

Sort By:
Pageof 24
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 17, 2016
Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort StudyLars I Gjærde, Leah Shepherd, Elzbieta Jablonowska, et al.
Eclinicalmedicine|September 14, 2019
Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort StudyCamilla Ingrid Hatleberg, Lene Ryom, David Kamara, et al.
AIDS (London, England)|December 27, 2018
Prior exposure to thymidine analogs and didanosine is associated with long-lasting alterations in adipose tissue distribution and cardiovascular risk factorsMarco Gelpi, Shoaib Afzal, Andreas Fuchs, et al.
CMAJ Open|December 9, 2014
The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort studyMarina B Klein, Jim Young, David Dunn, et al.
AIDS (London, England)|October 14, 2017
Abacavir use and risk of recurrent myocardial infarctionCaroline A Sabin, Lene Ryom, Antonella d'Arminio Monforte, et al.
Journal of the International AIDS Society|November 14, 2014
Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin AmericaAnne Marie Efsen, Anna Schultze, Frank Post, et al.
AIDS (London, England)|October 26, 2012
An internationally generalizable risk index for mortality after one year of antiretroviral therapyJanet P Tate, Amy C Justice, Michael D Hughes, et al.
The Journal of Infectious Diseases|September 11, 2019
Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) StudyLene Ryom, Jens Dilling Lundgren, Peter Reiss, et al.
The Lancet. HIV|November 2, 2015
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trialJose I Bernardino, Amanda Mocroft, Patrick W Mallon, et al.
The Journal of Infectious Diseases|July 9, 2020
The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D StudyLene Ryom, Jens D Lundgren, Peter Reiss, et al.
Pageof 24